Published in Clin Vaccine Immunol on September 07, 2011
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science (2009) 17.14
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science (2010) 14.91
Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science (1994) 13.54
Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol (1996) 11.91
Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature (2007) 11.73
A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol (1993) 10.75
Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One (2010) 5.73
A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (2001) 5.38
Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol (2004) 5.29
A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog (2010) 4.47
Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity (2005) 4.26
X-ray structures of the hexameric building block of the HIV capsid. Cell (2009) 4.08
Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol (2009) 3.85
The structural biology of HIV assembly. Curr Opin Struct Biol (2008) 3.71
Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Structure (2004) 3.31
Assembly properties of the human immunodeficiency virus type 1 CA protein. J Virol (2004) 3.09
Elicitation of structure-specific antibodies by epitope scaffolds. Proc Natl Acad Sci U S A (2010) 2.68
Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1. J Virol (1997) 2.60
Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization. Proc Natl Acad Sci U S A (1988) 2.37
Human immunodeficiency virus infection in two cohorts of homosexual men: neutralising sera and association of anti-gag antibody with prognosis. Lancet (1987) 2.34
Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody. J Virol (2006) 1.71
HIV-1-specific antibody responses during acute and chronic HIV-1 infection. Curr Opin HIV AIDS (2009) 1.67
Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1. J Virol (2006) 1.59
Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection. BMJ (1991) 1.48
Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization. J Mol Biol (2007) 1.42
Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant. PLoS One (2011) 1.41
Disulfide bond stabilization of the hexameric capsomer of human immunodeficiency virus. J Mol Biol (2010) 1.35
Viral evolution and escape during acute HIV-1 infection. J Infect Dis (2010) 1.26
Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects. Vaccine (2010) 1.15
Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold. Virology (2010) 1.10
Decline of anti-p24 antibody precedes antigenaemia as correlate of prognosis in HIV-1 infection. AIDS (1987) 1.09
Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity. Virology (2008) 1.05
Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference. Lancet Infect Dis (2010) 0.96
CD4+ T cell targeting of human immunodeficiency virus type 1 (HIV-1) peptide sequences present in vivo during chronic, progressive HIV-1 disease. Virology (2006) 0.77
Monoclonal antibodies to p24-core protein of HIV-1 mediate ADCC and inhibit virus spread in vitro. Clin Diagn Virol (1995) 0.77
Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer (2009) 3.33
Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections. Genomics (2013) 1.24
Evaluation of a combined triple method to detect causative HPV in oral and oropharyngeal squamous cell carcinomas: p16 Immunohistochemistry, Consensus PCR HPV-DNA, and In Situ Hybridization. Infect Agent Cancer (2012) 1.17
Analysis of human papillomavirus type-16 variants in Italian women with cervical intraepithelial neoplasia and cervical cancer. J Med Virol (2004) 1.13
Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol (2010) 1.09
Molecular signatures associated with HCV-induced hepatocellular carcinoma and liver metastasis. PLoS One (2013) 1.06
Update on Head and Neck Cancer: Current Knowledge on Epidemiology, Risk Factors, Molecular Features and Novel Therapies. Oncology (2015) 1.03
Prevalence of alpha-papillomavirus genotypes in cervical squamous intraepithelial lesions and invasive cervical carcinoma in the Italian population. J Med Virol (2006) 1.02
Incidence of breast cancer in Italy: mastectomies and quadrantectomies performed between 2000 and 2005. J Exp Clin Cancer Res (2009) 1.02
Prevalence of human papillomavirus types in high-grade cervical intraepithelial neoplasia and cancer in Italy. Cancer Epidemiol Biomarkers Prev (2010) 1.00
Effects of adjuvants on IgG subclasses elicited by virus-like particles. J Transl Med (2012) 0.99
Human papillomavirus genotypes and HPV16 variants in penile carcinoma. Int J Cancer (2008) 0.99
Immature monocyte derived dendritic cells gene expression profile in response to Virus-Like Particles stimulation. J Transl Med (2005) 0.98
Mutations of the TP53 gene in adenocarcinoma and squamous cell carcinoma of the cervix: a systematic review. Gynecol Oncol (2012) 0.97
Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference. Lancet Infect Dis (2010) 0.96
Human papillomavirus (HPV) genotypes and HPV16 variants in human immunodeficiency virus-positive Italian women. J Gen Virol (2008) 0.96
Challenges in cancer vaccine development for hepatocellular carcinoma. J Hepatol (2013) 0.95
Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma. J Transl Med (2009) 0.95
Virus-like particles as particulate vaccines. Curr HIV Res (2010) 0.94
Prevalence of human papillomavirus genotypes and their variants in high risk West Africa women immigrants in South Italy. Infect Agent Cancer (2007) 0.92
Gene expression profile of peripheral blood mononuclear cells in response to HIV-VLPs stimulation. BMC Bioinformatics (2008) 0.92
Translational fusion of chloroplast-expressed human papillomavirus type 16 L1 capsid protein enhances antigen accumulation in transplastomic tobacco. Transgenic Res (2008) 0.92
Virus-like particle vaccines and adjuvants: the HPV paradigm. Expert Rev Vaccines (2009) 0.91
Developments in virus-like particle-based vaccines for infectious diseases and cancer. Expert Rev Vaccines (2011) 0.91
Antigen-specific vaccines for cancer treatment. Hum Vaccin Immunother (2014) 0.89
Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention. Infect Agent Cancer (2008) 0.89
Screening of HIV-1 isolates by reverse heteroduplex mobility assay and identification of non-B subtypes in Italy. J Acquir Immune Defic Syndr (2004) 0.89
Human herpesvirus type 8 variants circulating in Europe, Africa and North America in classic, endemic and epidemic Kaposi's sarcoma lesions during pre-AIDS and AIDS era. Virology (2010) 0.89
Detection of mucosal and cutaneous human papillomaviruses in oesophagitis, squamous cell carcinoma and adenocarcinoma of the oesophagus. J Clin Virol (2009) 0.88
Dendritic cells in the pathogenesis and treatment of human diseases: a Janus Bifrons? Immunotherapy (2011) 0.87
Cardiac tamponade and heart failure due to myopericarditis as a presentation of infection with the pandemic H1N1 2009 influenza A virus. J Clin Microbiol (2010) 0.87
TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients. Infect Agent Cancer (2011) 0.87
Kaposi's sarcoma: etiology and pathogenesis, inducing factors, causal associations, and treatments: facts and controversies. Clin Dermatol (2013) 0.87
Systems biology applied to vaccine and immunotherapy development. BMC Syst Biol (2011) 0.85
High-level expression of the HIV-1 Pr55gag polyprotein in transgenic tobacco chloroplasts. Planta (2009) 0.84
Human papillomavirus infection in urine samples from male renal transplant patients. J Med Virol (2010) 0.83
Molecular immune signatures of HIV-1 vaccines in human PBMCs. FEBS Lett (2009) 0.83
New adjuvants in evolving vaccine strategies. Expert Opin Biol Ther (2011) 0.83
VLPs and particle strategies for cancer vaccines. Expert Rev Vaccines (2013) 0.83
MDM2 and CDKN1A gene polymorphisms and risk of Kaposi's sarcoma in African and Caucasian patients. Biomarkers (2010) 0.82
TP53 codon 72 polymorphism in classic, endemic and epidemic Kaposi's sarcoma in African and Caucasian patients. Oncology (2009) 0.82
A pilot study on the distribution of human papillomavirus genotypes and HPV-16 variants in cervical neoplastic lesions from Ecuadorian women. J Med Virol (2008) 0.82
TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix. J Transl Med (2014) 0.82
Immune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders. J Transl Med (2010) 0.82
Somatic mutations of STK11 gene in human papillomavirus positive and negative penile cancer. Infect Agent Cancer (2013) 0.82
Functional interaction between human papillomavirus type 16 E6 and E7 oncoproteins and cigarette smoke components in lung epithelial cells. PLoS One (2012) 0.82
Infectious agents and human malignancies. Front Biosci (Landmark Ed) (2009) 0.82
Genetic and phylogenetic evolution of HIV-1 in a low subtype heterogeneity epidemic: the Italian example. Retrovirology (2007) 0.82
Molecular and phylogenetic analysis of HIV-1 variants circulating in Italy. Infect Agent Cancer (2008) 0.81
Molecular epidemiology of human herpesvirus 8 variants in Kaposi's sarcoma from Iranian patients. Virus Res (2011) 0.81